Update: Public Health Service workshop on human T-lymphotropic virus type III antibody testing--United States
- PMID: 2991728
Update: Public Health Service workshop on human T-lymphotropic virus type III antibody testing--United States
Abstract
PIP: According to reports presented at a July 1985 US Public Health Service workshop on human T-lymphotropic virus type III (HTLV-III) antibody testing, enzyme immunoassay serologic tests in current use at blood banks, plasma collection centers, health departments, and other clinical settings are both highly sensitive and specific. HTLV-III antibody test data have been accumulated from over 1.1 million units of blood collected at 155 centers, 2831 (0.25%) of which were positive after repeated testing. The Atlanta Region of the American Red Cross and the Centers for Disease Control reported data from testing over 51,000 donors, 0.23% of whom were repeatedly reactive by the Abbott enzyme immunoassay test. 32% of repeatedly reactive tests were strongly reactive. Of 220 donors whose tests were initially reactive and subsequently negative, none had either a positive Western blot test or positive culture for HTLV-III virus. To determine the sensitivity of the Abbott test in high-risk persons, virus isolations were attempted from homosexual men in San Francisco. None of 70 men with negative HTLV-III antibody tests had a positive culture, while 43 (60%) of 72 men with repeatedly reactive tests were culture-positive. 97% of positive tests in this population were highly reactive. Weakly reactive enzyme immunoassay tests tend to correlate poorly with positive Western blot tests and are generally nonspecific for HTLV-III infection. Screening is judged to have so far removed as many as 1000 potentially infectious units of blood from the US blood supply.
Similar articles
-
Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus.MMWR Morb Mortal Wkly Rep. 1986 Mar 14;35(10):152-5. MMWR Morb Mortal Wkly Rep. 1986. PMID: 3005822
-
Human T-lymphotropic virus type III/lymphadenopathy-associated virus antibody testing at alternate sites.MMWR Morb Mortal Wkly Rep. 1986 May 2;35(17):284-7. MMWR Morb Mortal Wkly Rep. 1986. PMID: 3010070
-
Human T-lymphotropic virus type I/II. Status of enzyme immunoassay and western blot testing in the United States in 1989 and 1990.Arch Pathol Lab Med. 1992 May;116(5):471-6. Arch Pathol Lab Med. 1992. PMID: 1316110
-
Assessment of screening as a preventive technology: the example of HTLV-III/LAV antibody testing.Isr J Med Sci. 1986 Jul-Aug;22(7-8):524-8. Isr J Med Sci. 1986. PMID: 3640749
-
Clinical and molecular parameters of HTLV-I infection.Clin Lab Med. 1988 Mar;8(1):65-84. Clin Lab Med. 1988. PMID: 2896088 Review.
Cited by
-
AIDS and the obstetrician-gynecologist.J Natl Med Assoc. 1987 Oct;79(10):1057-67. J Natl Med Assoc. 1987. PMID: 3316672 Free PMC article. Review.
-
Risk of HIV infection on patients and staff of two dialysis centers: seroepidemiological findings and prevention trends.Eur J Epidemiol. 1988 Jun;4(2):171-4. doi: 10.1007/BF00144746. Eur J Epidemiol. 1988. PMID: 3042446
-
Management of infectious and immunological complications of acquired immunodeficiency syndrome (AIDS). Current and future prospects.Drugs. 1987 Jan;33(1):66-84. doi: 10.2165/00003495-198733010-00004. Drugs. 1987. PMID: 3545766 Review.